When Genzyme, a Massachusetts-based genetics research company, opened its new global headquarters in Cambridge on Saturday, everything went as planned – the urinals didn’t flush with water and the ...

PHILADELPHIA (Reuters) - Biotechnology company Genzyme Corp may be holding out for more money from suitor Sanofi-Aventis , but will find it difficult to persuade investors it is better off on its own.

PARIS/BOSTON (Reuters) - Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially ...

Genzyme Corp. and Dyax Corp. have ended a collaboration on their development of a drug called DX-88. Dyax said it will receive all the assets of the joint venture, full ownership of the drug, and a ...

In an ironic twist, Genzyme (www.genzyme.com) first battled through its acquisition of Bioenvision and is now basking in the glory of speculations over big pharma’s interest in gobbling up biologic ...

How do you whittle 35 years of headlining business news down to a couple thousand words and a few pages? You don't. But here, we take our best shot to highlight the companies, individuals, and moments ...

Sanofi-aventis CEO Chris Viebacher outlined the research and development strategy that led to the <a target="_blank" href="http://www.masshightech.com/stories/2011/02 ...

Monica Chou, Robert Schwartz Ph.D. Elevidys ® is a onetime adeno-associated virus vector-based gene therapy used to treat patients with Duchenne muscular dystrophy (“DMD”) caused by a mutation in the ...

Bayer stands to earn up to $1.9 billion dependent on approval and sales achievements. Genzyme is taking over worldwide rights from Bayer HealthCare covering Campath® (alemtuzumab), which is approved ...

NEW YORK (CBS.MW) -- Genzyme has agreed to acquire SangStat for about $600 million. The deal values SangStat shares at $22.50 each in cash, a hefty premium from Friday's close at $15.48. Genzyme ...

Sanofi-Aventis agreed to buy Genzyme Corp., ending a nine-month pursuit of the U.S. biotechnology company with a sweetened offer of at least $20.1 billion that gives France's biggest drugmaker ...